Profiel
Naresh K.
Nayyar is currently the Vice President-Regulatory Affairs at Turning Point Therapeutics, Inc. Prior to this, he worked as the Associate Vice President-Regulatory Affairs at aTyr Pharma, Inc. from 2016 to 2018.
Nayyar holds an MBA from the University of Phoenix and a doctorate from the University of Delhi.
Actieve functies van Naresh K. Nayyar
| Bedrijven | Functie | Begin |
|---|---|---|
| TURG POIN | General Counsel | 01-06-2018 |
Eerdere bekende functies van Naresh K. Nayyar
| Bedrijven | Functie | Einde |
|---|---|---|
| ATYR PHARMA, INC. | Corporate Officer/Principal | 01-05-2018 |
Opleiding van Naresh K. Nayyar
| University of Phoenix | Masters Business Admin |
| University of Delhi | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ATYR PHARMA, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
